A detailed history of Royal Bank Of Canada transactions in Macrogenics Inc stock. As of the latest transaction made, Royal Bank Of Canada holds 6,041 shares of MGNX stock, worth $19,693. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,041
Previous 6,032 0.15%
Holding current value
$19,693
Previous $25,000 24.0%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.0 - $5.55 $27 - $49
9 Added 0.15%
6,041 $19,000
Q2 2024

Aug 14, 2024

SELL
$3.31 - $18.51 $19,300 - $107,931
-5,831 Reduced 49.15%
6,032 $25,000
Q1 2024

Nov 05, 2024

BUY
$9.77 - $21.47 $56,968 - $125,191
5,831 Added 96.67%
11,863 $174,000
Q1 2024

May 15, 2024

SELL
$9.77 - $21.47 $165,835 - $364,431
-16,974 Reduced 58.86%
11,863 $174,000
Q4 2023

Feb 14, 2024

BUY
$4.48 - $10.11 $39,764 - $89,736
8,876 Added 44.47%
28,837 $277,000
Q3 2023

Nov 14, 2023

BUY
$4.48 - $6.19 $62,894 - $86,901
14,039 Added 237.07%
19,961 $93,000
Q2 2023

Aug 14, 2023

BUY
$4.62 - $7.54 $9,946 - $16,233
2,153 Added 57.12%
5,922 $31,000
Q1 2023

May 15, 2023

SELL
$4.82 - $7.24 $27,459 - $41,246
-5,697 Reduced 60.18%
3,769 $27,000
Q4 2022

Feb 14, 2023

BUY
$3.34 - $6.98 $27,762 - $58,017
8,312 Added 720.28%
9,466 $63,000
Q3 2022

Nov 14, 2022

BUY
$3.01 - $5.22 $2,453 - $4,254
815 Added 240.41%
1,154 $4,000
Q2 2022

Aug 15, 2022

SELL
$2.25 - $9.99 $13,387 - $59,440
-5,950 Reduced 94.61%
339 $1,000
Q1 2022

May 16, 2022

SELL
$8.12 - $16.9 $68,102 - $141,740
-8,387 Reduced 57.15%
6,289 $56,000
Q4 2021

Feb 14, 2022

BUY
$15.91 - $21.88 $112,117 - $154,188
7,047 Added 92.37%
14,676 $236,000
Q3 2021

Nov 15, 2021

BUY
$19.74 - $28.7 $19,542 - $28,413
990 Added 14.91%
7,629 $159,000
Q2 2021

Aug 16, 2021

BUY
$20.49 - $35.63 $136,033 - $236,547
6,639 New
6,639 $178,000

Others Institutions Holding MGNX

About MACROGENICS INC


  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $200M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.